The Effectiveness of Tecar Therapy in Management of Calf Muscle Strain Injuries (MS)
25. april 2026 oppdatert av: Nabil Mahmoud Ismail Abdel-Aal, Cairo University
this study will be conducted to investigate the effect of TECAR Therapy on quality of landing, healing and Function in patient with Calf Muscle Strain.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Calf muscle strain is one of the most common muscle injuries in high-performance athletes and contributes to substantial player downtime because of its high mean time to return to sport and occurrence during critical periods in the competitive season.
Published reports on lower-body muscle strain have provided frequent updates on the rehabilitation of high-profile muscle groups, such as the hamstring muscles, and improvements to calf strain management are seldom discussed despite the prevalence of these injuries in competitive sports.
In this article, we discuss the diagnosis, treatment, outcomes, risk factors, and prevention of calf muscle strain in athletes.Transfer of Electricity-Capacitive and Resistive (Tecar) therapy is considered a special form of energy that uses frequencies between 300 KHz and 1 MHz and is characterized as a non-invasive high-frequency energy that awakens the body's natural ability to self-regenerate.
Thus, it promotes the natural physiological processes of the tissue metabolically, transferring energy without introducing radiation from the external environment.
TECAR therapy stands out as a promising yet underexplored modality.
Its mechanism of action-utilizing both capacitive and resistive energy transfer-suggests a novel approach to addressing musculoskeletal injuries and pain.
While preliminary studies and clinical applications hint at its potential advantages, such as improved tissue healing and pain relief, a comprehensive evaluation of the existing research is necessary to fully understand the role of TECAR therapy in rehabilitation
Studietype
Intervensjonell
Registrering (Antatt)
60
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Nabil Abdel-Aal, professor
- Telefonnummer: 01200133613
- E-post: nabil.mahmoud@cu.edu.eg
Studer Kontakt Backup
- Navn: Hossam Mostafa, master
- Telefonnummer: 01092727746
- E-post: h.elshatory@gmail.com
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Aged between 16-39 years of age.
- not having suffered leg injuries in the past 6 months.
- not having suffered a triceps sural rupture in the past two years.
- be diagnosed with latent MTPs in the gastric-soleus complex through manual therapy in the dominant side.
- Presence of Calf muscles Strain evaluated by Ultrasonography.
- Athlete willing and able to participate in an exercise program safely.
- The radiologist also assessed whether the tendon ends could be reduced in passive plantar flexion of the ankle joint with the knee extended.
- Athlete BMI from 18.5 to 24.9 kg / m2
Exclusion Criteria:
- connective tissue pathology.
- lymphatic disorders (lymphadenopathy).
- Skin injuries (open wounds, infection, psoriasis, tattoos, hematoma).
- peripheral neuropathies.
- previous fractures.
- previous lower limb surgeries (in the past 12 months).
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: TECAR therapy
Thirty patients will receive TECAR therapy combined with conventional treatment three times per week for 12 weeks.
|
The TECAR intervention was administered to the calf muscle using the Zimmer devicein capacitive (CAP) mode for a duration of 20 min.
The therapy was applied with the signal at a variable power with a maximum of 300 W. The frequency used was 500 kHz with an intensity of 40%.
The intervention was standardized to a distal-to-proximal stroking rhythm with moderate pressure.
For the TECAR intervention, the capacitive (CAP) mode at 500 kHz with 40% intensity and a maximum power of 300 W was chosen to optimize deep tissue heating and promote local blood flow and tissue recovery.
The 20 min duration reflects protocols commonly used in therapeutic settings for muscle recovery and rehabilitation plus conventional therapy
the patients will receive stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee), eccentric exercises for calf muscles, plus plyometric exercises.
|
|
Aktiv komparator: conventional treatment
Thirty patients will receive conventional treatment three times per week for 12 weeks.
|
the patients will receive stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee), eccentric exercises for calf muscles, plus plyometric exercises.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
size of injury
Tidsramme: up to 12 weeks
|
ultrasonography device will be used to assess size of injury
|
up to 12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
landing error score system
Tidsramme: up to 12 weeks
|
Landing Error Scoring System is a clinical tool used to assess jump-landing mechanics for the video from my jumb land aplication .
the feet, ankle, knees, hip, trunk, shoulder, neck and head posture is assessed through the video.
it is a 17-item .
According to the performance sheet, the questions 1-15 are Yes/No questions that are rated as 0 or 1.
The questions 16 are rated as 0, 1, and 2; 0 = soft, 1= average and 2= stiff.
the question 17 are rated as 0,1,2; 0= excellent,1 average and 2= poor, so the total score ranges from zero to 19.
A higher score indicates poor technique in landing from a jump; a lower score indicates better jump-landing technique.
the score are categorized as excellent which less than 4, good score more than four and less than or equal 5, moderate score less than four and poor more than six
|
up to 12 weeks
|
|
jump height
Tidsramme: up to 12 weeks
|
The vertical jump test was performed as a one-legged counter movement jump (CMJ).
Starting position was in an upright position with the hands placed behind the back.
The subjects quickly bent the knee as much as desired and then immediately jumped upward attempting to maximize the height jumped.
The subjects performed three maximal approved trials for each leg, starting with the right and alternating between the right and the left leg.
However, if the subject increased hop performance in all three jumps, additional jumps were performed until no increase was seen.
The best jump height for each leg was used for data analysis.
|
up to 12 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. mai 2026
Primær fullføring (Antatt)
1. desember 2026
Studiet fullført (Antatt)
1. desember 2026
Datoer for studieregistrering
Først innsendt
25. april 2026
Først innsendt som oppfylte QC-kriteriene
25. april 2026
Først lagt ut (Faktiske)
1. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
1. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. april 2026
Sist bekreftet
1. april 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P.T.REC/012/006406
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .